2-azaniumyl-6-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]hexanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 英文名称: 2-azaniumyl-6-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]hexanoate
• 化学式: C16H28N4O4S
• 分子量: 372.5
• InChiKey: BAQMYDQNMFBZNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  159
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• [EN] TRIPARTITE MODULATORS OF ENDOSOMAL G PROTEIN-COUPLED RECEPTORS<br/>[FR] MODULATEURS TRIPARTITES DE RÉCEPTEURS COUPLÉS AUX PROTÉINES G DES ENDOSOMES
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2017112792A1

  公开（公告）日：2017-06-29

  The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.

  本发明涉及三部分化合物，包括用于内体高尔基蛋白偶联受体（如神经激肽-1受体）的调节子基团，一个连接物和一个适合将三部分化合物锚定到细胞膜的脂质锚。本发明还涉及一种前药和含有三部分化合物的药物组合物，以及利用三部分化合物治疗由内体高尔基蛋白偶联受体信号传导介导的疾病或紊乱的用途。
• [EN] CONJUGATES FOR TREATING DISEASES<br/>[FR] CONJUGUÉS POUR LE TRAITEMENT DE MALADIES
  申请人：ENDOCYTE INC

  公开号：WO2016148674A1

  公开（公告）日：2016-09-22

  The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.

  本公开涉及吡咯苯并二氮杂环（PBD）前药及其结合物。本公开还涉及所述结合物的药物组合物，制备方法和使用方法。
• [EN] RAF-DEGRADING CONJUGATE COMPOUNDS<br/>[FR] COMPOSÉS CONJUGUÉS DE DÉGRADATION DE RAF
  申请人：QUARTZ THERAPEUTICS INC

  公开号：WO2018200981A1

  公开（公告）日：2018-11-01

  The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF- Degrading Conjugate Compound.

  本公开提供了用于治疗癌症和其他与RAF相关疾病的RAF降解共轭化合物。还提供了药物组合物、治疗方法和包含RAF降解共轭化合物的试剂盒。
• Administrative agents via the SMVT transporter
  申请人：XenoPort, Inc.

  公开号：US20030158089A1

  公开（公告）日：2003-08-21

  Disclosed herein are conjugates comprising a therapeutic agent (e.g., a drug) which is linked to a conjugate moiety that is itself, or itself in combination with the agent, is a good substrate for the sodium dependent multi-vitamin transporter (SMVT). The conjugates have a molecular weight below 1500 daltons and exhibit increased uptake via SMVT through the cells lining the gastrointestinal lumen, and hence higher bioavailability, when administered orally compared to the therapeutic agent itself Also disclosed are methods of delivering agents that, as a result of linkage to a conjugate moiety, are good substrates of the SMVT transporter. Further disclosed are methods of screening conjugates or conjugate moieties, linked or linkable to a therapeutic agent, for capacity to be transported as substrates through the SMVT transporter.

  本文披露了包含治疗剂（例如药物）的共轭物，该治疗剂与一个共轭基团连接，该共轭基团本身或与该治疗剂结合后是钠依赖性多维生素转运蛋白（SMVT）的良好底物。这些共轭物的分子量低于1500道尔顿，并且通过肠道腔内细胞的SMVT表现出增加的摄取，因此在口服给药时具有更高的生物利用度，与治疗剂本身相比。还披露了通过连接到共轭基团的药剂而成为SMVT转运蛋白的良好底物的传递方法。此外，还披露了筛选共轭物或共轭基团的方法，这些共轭物或共轭基团与治疗剂连接或可连接，具有作为底物通过SMVT转运蛋白进行转运的能力。
• [EN] DUAL DISULFIDE DRUG CONJUGATES<br/>[FR] CONJUGUÉS DE MÉDICAMENTS À DEUX GROUPES DISULFURE
  申请人：ENDOCYTE INC

  公开号：WO2016168471A1

  公开（公告）日：2016-10-20

  The invention described herein pertains to dual disulfide drug conjugates. In particular, the invention described herein pertains to dual disulfide drug conjugates that target the folate receptor for delivery of conjugated drugs to a mammalian recipient. Also described are methods of making and using dual disulfide drug conjugates.

  本发明涉及双二硫醚药物共轭物。具体而言，本发明涉及双二硫醚药物共轭物，其靶向叶酸受体，用于将共轭药物传递给哺乳动物接受者。还描述了制备和使用双二硫醚药物共轭物的方法。